Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
about
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo.Clinical developments in nanotechnology for cancer therapy.Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.
P2860
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@en
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@nl
type
label
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@en
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@nl
prefLabel
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@en
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@nl
P2860
P356
P1433
P1476
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
@en
P2093
Jackie M Nemunaitis
John Nemunaitis
P2860
P304
P356
10.2217/14796694.4.6.759
P407
P577
2008-12-01T00:00:00Z